Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

VHH characterization.Recombinant VHHs: Production, characterization and affinity.

Chabrol E, Stojko J, Nicolas A, Botzanowski T, Fould B, Antoine M, Cianférani S, Ferry G, Boutin JA.

Anal Biochem. 2019 Oct 30;589:113491. doi: 10.1016/j.ab.2019.113491. [Epub ahead of print]

PMID:
31676284
2.

Antimalarial Properties of Dunnione Derivatives as NQO2 Substrates.

Chhour M, Aubouy A, Bourgeade-Delmas S, Pério P, Ternet-Fontebasso H, Haidara M, Ferry G, Nepveu F, Boutin JA, Reybier K.

Molecules. 2019 Oct 15;24(20). pii: E3697. doi: 10.3390/molecules24203697.

3.

VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH.

Hartmann L, Botzanowski T, Galibert M, Jullian M, Chabrol E, Zeder-Lutz G, Kugler V, Stojko J, Strub JM, Ferry G, Frankiewicz L, Puget K, Wagner R, Cianférani S, Boutin JA.

Protein Sci. 2019 Oct;28(10):1865-1879. doi: 10.1002/pro.3712. Epub 2019 Aug 29.

PMID:
31423659
4.

The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cells.

Jacoupy M, Hamon-Keromen E, Ordureau A, Erpapazoglou Z, Coge F, Corvol JC, Nosjean O, Mannoury la Cour C, Millan MJ, Boutin JA, Harper JW, Brice A, Guedin D, Gautier CA, Corti O.

Sci Rep. 2019 Aug 14;9(1):11829. doi: 10.1038/s41598-019-47352-9.

5.

Importance of the Choice of a Recombinant System to Produce Large Amounts of Functional Membrane Protein hERG.

Vasseur L, Cens T, Wagner R, Saint N, Kugler V, Chavanieu A, Ouvry C, Dupré C, Ferry G, Boutin JA.

Int J Mol Sci. 2019 Jun 28;20(13). pii: E3181. doi: 10.3390/ijms20133181.

6.

General lack of structural characterization of chemically synthesized long peptides.

Boutin JA, Tartar AL, van Dorsselaer A, Vaudry H.

Protein Sci. 2019 May;28(5):857-867. doi: 10.1002/pro.3601. Epub 2019 Mar 25. Review.

PMID:
30851143
7.

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization.

Boutin JA, Bouillaud F, Janda E, Gacsalyi I, Guillaumet G, Hirsch EC, Kane DA, Nepveu F, Reybier K, Dupuis P, Bertrand M, Chhour M, Le Diguarher T, Antoine M, Brebner K, Da Costa H, Ducrot P, Giganti A, Goswami V, Guedouari H, Michel PP, Patel A, Paysant J, Stojko J, Viaud-Massuard MC, Ferry G.

Mol Pharmacol. 2019 Mar;95(3):269-285. doi: 10.1124/mol.118.114231. Epub 2018 Dec 19.

8.

Is There Sufficient Evidence that the Melatonin Binding Site MT3 Is Quinone Reductase 2?

Boutin JA, Ferry G.

J Pharmacol Exp Ther. 2019 Jan;368(1):59-65. doi: 10.1124/jpet.118.253260. Epub 2018 Nov 2. Review.

PMID:
30389722
9.

Design, Synthesis, Molecular Dynamics Simulation, and Functional Evaluation of a Novel Series of 26RFa Peptide Analogues Containing a Mono- or Polyalkyl Guanidino Arginine Derivative.

Alim K, Lefranc B, Sopkova-de Oliveira Santos J, Dubessy C, Picot M, Boutin JA, Vaudry H, Chartrel N, Vaudry D, Chuquet J, Leprince J.

J Med Chem. 2018 Nov 21;61(22):10185-10197. doi: 10.1021/acs.jmedchem.8b01332. Epub 2018 Nov 7.

PMID:
30358997
10.

Gene expression profiling during hibernation in the European hamster.

Gautier C, Bothorel B, Ciocca D, Valour D, Gaudeau A, Dupré C, Lizzo G, Brasseur C, Riest-Fery I, Stephan JP, Nosjean O, Boutin JA, Guénin SP, Simonneaux V.

Sci Rep. 2018 Sep 3;8(1):13167. doi: 10.1038/s41598-018-31506-2.

11.

Hamster Melatonin Receptors: Cloning and Binding Characterization of MT₁ and Attempt to Clone MT₂.

Gautier C, Dufour E, Dupré C, Lizzo G, Caignard S, Riest-Fery I, Brasseur C, Legros C, Delagrange P, Nosjean O, Simonneaux V, Boutin JA, Guenin SP.

Int J Mol Sci. 2018 Jul 4;19(7). pii: E1957. doi: 10.3390/ijms19071957.

12.

Natural Inhibitors of the RhoA-p115 Complex from the Bark of Meiogyne baillonii.

Olivon F, Nothias LF, Dumontet V, Retailleau P, Berger S, Ferry G, Cohen W, Pfeiffer B, Boutin JA, Scalbert E, Roussi F, Litaudon M.

J Nat Prod. 2018 Jul 27;81(7):1610-1618. doi: 10.1021/acs.jnatprod.8b00209. Epub 2018 Jul 3.

PMID:
29969260
13.

A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot.

Petit AP, Garcia-Petit C, Bueren-Calabuig JA, Vuillard LM, Ferry G, Boutin JA.

J Biol Chem. 2018 Jun 8;293(23):9064-9077. doi: 10.1074/jbc.RA117.001123. Epub 2018 Apr 25.

14.

GHSR-D2R heteromerization modulates dopamine signaling through an effect on G protein conformation.

Damian M, Pons V, Renault P, M'Kadmi C, Delort B, Hartmann L, Kaya AI, Louet M, Gagne D, Ben Haj Salah K, Denoyelle S, Ferry G, Boutin JA, Wagner R, Fehrentz JA, Martinez J, Marie J, Floquet N, Galès C, Mary S, Hamm HE, Banères JL.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4501-4506. doi: 10.1073/pnas.1712725115. Epub 2018 Apr 9.

15.

Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus).

Gautier C, Guenin SP, Riest-Fery I, Perry TJ, Legros C, Nosjean O, Simonneaux V, Grützner F, Boutin JA.

PLoS One. 2018 Mar 12;13(3):e0191904. doi: 10.1371/journal.pone.0191904. eCollection 2018.

16.

Oxidative stress and neurodegeneration: The possible contribution of quinone reductase 2.

Cassagnes LE, Chhour M, Pério P, Sudor J, Gayon R, Ferry G, Boutin JA, Nepveu F, Reybier K.

Free Radic Biol Med. 2018 May 20;120:56-61. doi: 10.1016/j.freeradbiomed.2018.03.002. Epub 2018 Mar 8.

PMID:
29526807
17.

Assessments of cellular melatonin receptor signaling pathways: β-arrestin recruitment, receptor internalization, and impedance variations.

Dupré C, Bruno O, Bonnaud A, Giganti A, Nosjean O, Legros C, Boutin JA.

Eur J Pharmacol. 2018 Jan 5;818:534-544. doi: 10.1016/j.ejphar.2017.11.022. Epub 2017 Nov 15.

PMID:
29154938
18.

Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction.

Gerard CJJ, Ferry G, Vuillard LM, Boutin JA, Chavas LMG, Huet T, Ferte N, Grossier R, Candoni N, Veesler S.

Acta Crystallogr F Struct Biol Commun. 2017 Oct 1;73(Pt 10):574-578. doi: 10.1107/S2053230X17013826. Epub 2017 Oct 2.

19.

Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBα/NCoR.

Westermaier Y, Ruiz-Carmona S, Theret I, Perron-Sierra F, Poissonnet G, Dacquet C, Boutin JA, Ducrot P, Barril X.

J Comput Aided Mol Des. 2017 Aug;31(8):755-775. doi: 10.1007/s10822-017-0040-7. Epub 2017 Jul 15.

PMID:
28712038
20.

New MT₂ Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists.

Boutin JA, Bonnaud A, Brasseur C, Bruno O, Lepretre N, Oosting P, Coumailleau S, Delagrange P, Nosjean O, Legros C.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1347. doi: 10.3390/ijms18071347.

21.

W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway.

Li T, Lin GY, Zhong L, Zhou Y, Wang J, Zhu Y, Feng Y, Cai XQ, Liu Q, Nosjean O, Boutin JA, Renard P, Yang DH, Wang MW.

Acta Pharmacol Sin. 2017 Jul;38(7):1024-1037. doi: 10.1038/aps.2017.15. Epub 2017 May 15.

22.

Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery.

Vénien-Bryan C, Li Z, Vuillard L, Boutin JA.

Acta Crystallogr F Struct Biol Commun. 2017 Apr 1;73(Pt 4):174-183. doi: 10.1107/S2053230X17003740. Epub 2017 Mar 29. Review.

23.

Role of Quinone Reductase 2 in the Antimalarial Properties of Indolone-Type Derivatives.

Cassagnes LE, Rakotoarivelo N, Sirigu S, Pério P, Najahi E, Chavas LM, Thompson A, Gayon R, Ferry G, Boutin JA, Valentin A, Reybier K, Nepveu F.

Molecules. 2017 Jan 30;22(2). pii: E210. doi: 10.3390/molecules22020210.

24.

New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation.

Landagaray E, Ettaoussi M, Rami M, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2017 Feb 15;127:621-631. doi: 10.1016/j.ejmech.2016.12.013. Epub 2017 Jan 3.

PMID:
28131094
25.

Screening ubiquitin specific protease activities using chemically synthesized ubiquitin and ubiquitinated peptides.

Bacchi M, Fould B, Jullian M, Kreiter A, Maurras A, Nosjean O, Coursindel T, Puget K, Ferry G, Boutin JA.

Anal Biochem. 2017 Feb 15;519:57-70. doi: 10.1016/j.ab.2016.12.014. Epub 2016 Dec 18.

PMID:
27993553
26.

Total chemical synthesis, refolding, and crystallographic structure of fully active immunophilin calstabin 2 (FKBP12.6).

Bacchi M, Jullian M, Sirigu S, Fould B, Huet T, Bruyand L, Antoine M, Vuillard L, Ronga L, Chavas LM, Nosjean O, Ferry G, Puget K, Boutin JA.

Protein Sci. 2016 Dec;25(12):2225-2242. doi: 10.1002/pro.3051. Epub 2016 Oct 13.

27.

[Cryo-microscopy, an alternative to the X-ray crystallography?].

Boutin JA, Li Z, Vuillard L, Vénien-Bryan C.

Med Sci (Paris). 2016 8-9;32(8-9):758-67. doi: 10.1051/medsci/20163208025. Epub 2016 Sep 12. Review. French.

28.

Piceatannol and resveratrol share inhibitory effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue, but differ in their antilipolytic properties.

Les F, Deleruyelle S, Cassagnes LE, Boutin JA, Balogh B, Arbones-Mainar JM, Biron S, Marceau P, Richard D, Nepveu F, Mauriège P, Carpéné C.

Chem Biol Interact. 2016 Oct 25;258:115-25. doi: 10.1016/j.cbi.2016.07.014. Epub 2016 Jul 28.

PMID:
27475863
29.

Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.

Mollica L, Theret I, Antoine M, Perron-Sierra F, Charton Y, Fourquez JM, Wierzbicki M, Boutin JA, Ferry G, Decherchi S, Bottegoni G, Ducrot P, Cavalli A.

J Med Chem. 2016 Aug 11;59(15):7167-76. doi: 10.1021/acs.jmedchem.6b00632. Epub 2016 Jul 22.

PMID:
27391254
30.

High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes.

Bedut S, Seminatore-Nole C, Lamamy V, Caignard S, Boutin JA, Nosjean O, Stephan JP, Coge F.

Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H44-53. doi: 10.1152/ajpheart.00793.2015. Epub 2016 May 3.

31.

Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.

Landagaray E, Ettaoussi M, Duroux R, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2016 Feb 15;109:360-70. doi: 10.1016/j.ejmech.2015.12.047. Epub 2015 Dec 29.

PMID:
26820449
32.

Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.

Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA.

J Pharmacol Exp Ther. 2016 Mar;356(3):681-92. doi: 10.1124/jpet.115.229989. Epub 2016 Jan 12.

PMID:
26759496
33.

Detergent-free Isolation of Functional G Protein-Coupled Receptors into Nanometric Lipid Particles.

Logez C, Damian M, Legros C, Dupré C, Guéry M, Mary S, Wagner R, M'Kadmi C, Nosjean O, Fould B, Marie J, Fehrentz JA, Martinez J, Ferry G, Boutin JA, Banères JL.

Biochemistry. 2016 Jan 12;55(1):38-48. doi: 10.1021/acs.biochem.5b01040. Epub 2015 Dec 24.

PMID:
26701065
34.

Quinone reductase 2 as a promising target of melatonin therapeutic actions.

Boutin JA.

Expert Opin Ther Targets. 2016;20(3):303-17. doi: 10.1517/14728222.2016.1091882. Epub 2015 Oct 14. Review.

PMID:
26465080
35.

In cellulo monitoring of quinone reductase activity and reactive oxygen species production during the redox cycling of 1,2 and 1,4 quinones.

Cassagnes LE, Perio P, Ferry G, Moulharat N, Antoine M, Gayon R, Boutin JA, Nepveu F, Reybier K.

Free Radic Biol Med. 2015 Dec;89:126-34. doi: 10.1016/j.freeradbiomed.2015.07.150. Epub 2015 Sep 18.

PMID:
26386287
36.

Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.

Spadoni G, Bedini A, Lucarini S, Mari M, Caignard DH, Boutin JA, Delagrange P, Lucini V, Scaglione F, Lodola A, Zanardi F, Pala D, Mor M, Rivara S.

J Med Chem. 2015 Sep 24;58(18):7512-25. doi: 10.1021/acs.jmedchem.5b01066.

PMID:
26334942
37.

Molecular mechanisms of transcriptional control by Rev-erbα: An energetic foundation for reconciling structure and binding with biological function.

Vaissière A, Berger S, Harrus D, Dacquet C, Le Maire A, Boutin JA, Ferry G, Royer CA.

Protein Sci. 2015 Jul;24(7):1129-46. doi: 10.1002/pro.2701. Epub 2015 Jun 11.

38.

¹⁹F nuclear magnetic resonance screening of glucokinase activators.

Assemat O, Antoine M, Fourquez JM, Wierzbicki M, Charton Y, Hennig P, Perron-Sierra F, Ferry G, Boutin JA, Delsuc MA.

Anal Biochem. 2015 May 15;477:62-8. doi: 10.1016/j.ab.2015.02.006. Epub 2015 Feb 12.

PMID:
25684110
39.

Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).

Ettaoussi M, Pérès B, Errazani A, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2015 Jan 27;90:822-33. doi: 10.1016/j.ejmech.2014.12.021. Epub 2014 Dec 13.

PMID:
25528336
40.

Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes.

Logez C, Berger S, Legros C, Banères JL, Cohen W, Delagrange P, Nosjean O, Boutin JA, Ferry G, Simonin F, Wagner R.

PLoS One. 2014 Jun 24;9(6):e100616. doi: 10.1371/journal.pone.0100616. eCollection 2014.

41.

Molecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies.

Neveu C, Dulin F, Lefranc B, Galas L, Calbrix C, Bureau R, Rault S, Chuquet J, Boutin JA, Guilhaudis L, Ségalas-Milazzo I, Vaudry D, Vaudry H, Santos JS, Leprince J.

Br J Pharmacol. 2014 Oct;171(19):4425-39. doi: 10.1111/bph.12808. Epub 2014 Sep 5.

42.

Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions.

Legros C, Chesneau D, Boutin JA, Barc C, Malpaux B.

J Neuroendocrinol. 2014 Mar;26(3):151-63. doi: 10.1111/jne.12134.

PMID:
24460899
43.

New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.

Landagaray E, Ettaoussi M, Leclerc V, Traoré B, Perez V, Nosjean O, Boutin JA, Caignard DH, Delagrange P, Berthelot P, Yous S.

Bioorg Med Chem. 2014 Feb 1;22(3):986-96. doi: 10.1016/j.bmc.2013.12.054. Epub 2014 Jan 3.

PMID:
24417958
44.

Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state.

Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, Boutin JA, Nosjean O.

Br J Pharmacol. 2014 Jan;171(1):186-201. doi: 10.1111/bph.12457.

45.

Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.

Ettaoussi M, Sabaouni A, Pérès B, Landagaray E, Nosjean O, Boutin JA, Caignard DH, Delagrange P, Berthelot P, Yous S.

ChemMedChem. 2013 Nov;8(11):1830-45. doi: 10.1002/cmdc.201300294. Epub 2013 Sep 12.

PMID:
24031039
46.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

47.

New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.

Legros C, Matthey U, Grelak T, Pedragona-Moreau S, Hassler W, Yous S, Thomas E, Suzenet F, Folleas B, Lefoulon F, Berthelot P, Caignard DH, Guillaumet G, Delagrange P, Brayer JL, Nosjean O, Boutin JA.

Int J Mol Sci. 2013 Apr 25;14(5):8948-62. doi: 10.3390/ijms14058948.

48.

Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models.

Della-Zuana O, Audinot V, Levenez V, Ktorza A, Presse F, Nahon JL, Boutin JA.

Front Endocrinol (Lausanne). 2012 Dec 21;3:160. doi: 10.3389/fendo.2012.00160. eCollection 2012.

49.

Effect of oxime ether incorporation in acyl indole derivatives on PPAR subtype selectivity.

Le Naour M, Leclerc V, Farce A, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Lonchampt M, Dacquet C, Ktorza A, Berthelot P, Lebegue N.

ChemMedChem. 2012 Dec;7(12):2179-93. doi: 10.1002/cmdc.201200316. Epub 2012 Oct 9.

PMID:
23047286
50.

Rational design of a low molecular weight, stable, potent, and long-lasting GPR103 aza-β3-pseudopeptide agonist.

Neveu C, Lefranc B, Tasseau O, Do-Rego JC, Bourmaud A, Chan P, Bauchat P, Le Marec O, Chuquet J, Guilhaudis L, Boutin JA, Ségalas-Milazzo I, Costentin J, Vaudry H, Baudy-Floc'h M, Vaudry D, Leprince J.

J Med Chem. 2012 Sep 13;55(17):7516-24. doi: 10.1021/jm300507d. Epub 2012 Aug 17.

PMID:
22800498

Supplemental Content

Loading ...
Support Center